New drug aims to calm severe agitation in kids with mental health conditions

NCT ID NCT05025605

First seen Apr 03, 2026 · Last updated May 08, 2026 · Updated 4 times

Summary

This study tests an experimental drug called BXCL501 to see if it can safely reduce agitation in children and teenagers aged 10-17 who have schizophrenia or bipolar disorder. The trial involves 140 participants and measures changes in agitation using a standard rating scale. The goal is to find a fast-acting treatment for acute episodes of agitation in this young population.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • BioXcel Clinical Research Site

    RECRUITING

    Anaheim, California, 92805, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • BioXcel Clinical Research Site

    COMPLETED

    Atlanta, Georgia, 30331, United States

  • BioXcel Clinical Research Site

    RECRUITING

    DeSoto, Texas, 75115, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Bioxcel Clinical Research Site

    RECRUITING

    Hialeah, Florida, 33016, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Bioxcel Clinical Research Site

    RECRUITING

    Decatur, Georgia, 30030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.